Business Wire

CA-YUBICO

6.5.2024 15:01:34 CEST | Business Wire | Press release

Share
Yubico’s Key Product Innovations Empower Enterprise Security and Phishing-Resistant Passwordless Authentication at Scale

Today Yubico (NASDAQ: YUBICO), the leading provider of hardware authentication security keys, announced the upcoming release of YubiKey 5.7 firmware for the YubiKey 5 Series, Security Key Series and Security Key Series - Enterprise Edition. With a focus on enterprise needs, these updates reinforce Yubico’s commitment to providing secure, simple, and scalable authentication solutions. Security keys with firmware 5.7 will be available to purchase in late May 2024, offering enhanced features such as improved PIN complexity, enterprise attestation, and expanded passkey credentials storage. These updates empower organizations to adopt passwordless-first, modern authentication, fostering phishing-resistant users worldwide.

As part of Yubico’s goal of helping enterprises raise the bar for security with greater flexibility, the company also announced the availability of Yubico Authenticator 7 which will support the upcoming YubiKey 5.7 features.

“Organizations are continuing to face a surge in the variety and complexity of cyber threats at historical rates, often fueled by compromised employee login credentials, frequently resulting from attacks such as phishing. This trend is exacerbated by the rise in use of Artificial Intelligence (AI),” said Jeff Wallace, senior vice president of product at Yubico. “We’re excited to continue offering best-in-class solutions that protect organizations and accelerate their transition to passwordless with the latest enterprise-focused updates to the YubiKey. We’re confident that organizations are now better equipped than ever to enforce compliance requirements and elevate their security posture throughout their organization.”

YubiKey 5.7: Accelerating enterprises to passwordless

To help organizations tackle this challenge, Yubico’s key updates and enhancements to the YubiKey 5 Series and Security Key Series* include:

  • Enhanced PIN complexity across all YubiKey applications
    • Block simple patterns and common PINs at the hardware level to enable compliance with upcoming NIST requirements and corporate mandates. This includes FIDO2, PIV, and OpenPGP.
  • Enterprise attestation
    • Allow organizations to enforce the usage of YubiKeys that they purchased via custom programmed keys with enterprise attestation. Working in conjunction with identity providers, this capability can also facilitate the retrieval of unique identifiers during FIDO2 registration to streamline asset tracking and account recovery.
  • FIDO2 enhancements
    • Empower organizations to enforce compliance requirements and elevate security measures surrounding PIN usage. YubiKey 5.7 implements FIDO Client-to-Authenticator Protocol (CTAP) 2.1, embracing the latest FIDO2 protocol features such as Force PIN Change and Minimum PIN Length.
  • Expanded passkey and passwordless storage
    • Provide ample storage space to meet authentication needs while maintaining strong security standards. More storage for FIDO2 discoverable credentials (passkeys) and OATH one-time passwords will now accommodate up to 100 passkeys, 24 PIV certificates, 64 OATH seeds, and 2 OTP seeds at once for a total of 190 credentials.
  • Expansion and enhancement of public key algorithms for PIV applications
    • Align with DoD memo requirements and offer advanced key management functions, enhancing flexibility for organizations through support of larger RSA keys (RSA-3072 and RSA-4096), as well as Ed25519 and X25519 key types.
  • Migration to Yubico’s own cryptographic library
    • Yubico has developed a library in-house that performs the underlying cryptographic operations (decryption, signing, etc.) for RSA and ECC.

“The new features within 5.7 allow enterprises to streamline critical processes such as asset tracking and account recovery, while also enhancing flexibility,” said Wallace. “These updates empower enterprises with the latest authentication advancements and tools to build specific strategies for creating phishing-resistant users and mitigating phishing threats for employees, external identities, and customers.”

Capabilities in the new 5.7 YubiKeys also align with recent U.S. Government memo requirements on adopting phishing-resistant MFA and offer advanced key management functions. Compliance with upcoming NIST requirements and corporate mandates is also supported by enforcing the blocking of simple patterns and common PINs at the hardware level.

*Note: Smart Card/PIV capabilities, OATH and OTP credentials are not available on any Security Key Series thus these updates are not applicable. Enterprise attestation is available on the YubiKey 5 Series and Security Key Series - Enterprise Edition. See here for more details.

Yubico Authenticator 7: Hardware-backed authenticator app across desktop and mobile

Aligned with the 5.7 firmware release, significant updates within Yubico Authenticator 7 launched today in support of managing these new features. This new version enables use of the new public key algorithms for PIV, bringing more advanced management options and streamlines the interface for a better user experience when handling many credentials. Additionally, it adds localization with official support for French and Japanese, with additional community-provided translations. The app is now available for all major desktop platforms, as well as for Android. Enhanced features for iOS will be coming in the next version of the iOS application. It's the perfect companion to the new YubiKey 5.7, with its expanded credential storage.

The Yubico Authenticator delivers strong security by enabling users to store credentials on a YubiKey instead of a mobile phone, thereby significantly removing risks posed by remote attackers targeting software-based authenticator apps. By incorporating hardware-backed strong two-factor authentication in the YubiKey, credentials stays safe and the bar for security is raised while delivering the convenience of an authenticator app.

For more information on today’s innovation announcements from Yubico, visit here. To get the Yubico Authenticator 7 app, visit here.

About Yubico

Yubico (Nasdaq First North Growth Market Stockholm: YUBICO), the inventor of the YubiKey, offers the gold standard for phishing-resistant multi-factor authentication (MFA), stopping account takeovers in their tracks and making secure login easy and available for everyone. Since the company was founded in 2007, it has been a leader in setting global standards for secure access to computers, mobile devices, servers, browsers, and internet accounts. Yubico is a creator and core contributor to the FIDO2, WebAuthn, and FIDO Universal 2nd Factor (U2F) open authentication standards, and is a pioneer in delivering modern, hardware-based passkey authentication security at scale to customers in over 160 countries.

Yubico’s solutions enable passwordless logins using the most secure form of passkey technology. YubiKeys work out-of-the-box across hundreds of consumer and enterprise applications and services, delivering strong security with a fast and easy experience.

As part of its mission to make the internet more secure for everyone, Yubico donates YubiKeys to organizations helping at-risk individuals through the philanthropic initiative, Secure it Forward. The company is headquartered in Stockholm and Santa Clara, CA. For more information on Yubico, visit us at www.yubico.com.

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

View source version on businesswire.com: https://www.businesswire.com/news/home/20240506185894/en/

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com
DK

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

FPT Named an OpenAI Select Partner6.8.2026 02:00:00 CEST | Press release

Global IT corporation FPT today announced that it has been named an OpenAI Select Partner within the OpenAI Partner Network. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260805503787/en/ FPT Named an OpenAI Select Partner The OpenAI Partner Network is a global program for partners to build, sell, and deliver AI solutions with OpenAI. It brings together partners with deep industry expertise, delivery capabilities, and customer relationships while equipping them with resources, enablement, and support to help enterprises adopt OpenAI frontier models and products and turn them into measurable impact. As an OpenAI Select Partner, FPT will continue working with OpenAI to help organizations build, deploy, and scale AI solutions responsibly and effectively. This work will help organizations get more useful work from every token and stronger performance per dollar with GPT‑5.6, while using ChatGPT Work to turn ambitious goals into

U.S. FDA Approves Takeda’s ORZEYFUL™ (oveporexton), the First and Only Medicine to Treat the Underlying Cause of Narcolepsy Type 16.8.2026 00:10:00 CEST | Press release

Adults Taking ORZEYFUL Experienced Significant and Meaningful Improvements Across the Full Range of Symptoms of Narcolepsy Type 1 (NT1) in Clinical Trials Compared to Those on Placebo As a First-in-Class Orexin Treatment, ORZEYFUL has the Potential to Redefine NT1 Care Beyond Individual Symptoms Takeda is Advancing U.S. Launch Preparations and Expects to Make ORZEYFUL Available Following Completion of the Drug Enforcement Administration (DEA) Scheduling Process Takeda (TSE:4502/NYSE:TAK) announced that the U.S. Food and Drug Administration (FDA) approved ORZEYFUL™ (oveporexton), an oral orexin receptor 2 (OX2R) agonist, for the treatment of narcolepsy type 1 (NT1, narcolepsy with cataplexy) in adults.* The persistent 24-hour nature of NT1 is driven by orexin deficiency and can severely impact people’s lives. As a first-in-class orexin treatment, ORZEYFUL is the only medicine indicated in the U.S. to treat the disease holistically rather than individual symptoms. “The FDA approval of OR

Compass Pathways Announces New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)5.8.2026 22:30:00 CEST | Press release

Compass Pathways plc (Nasdaq: CMPS), a biotechnology company dedicated to unlocking urgently needed new treatment options in mental health care, announced today that Compass granted equity awards under the Compass Pathways plc 2026 Inducement Plan to fourteen newly hired non-executive employees. The equity awards were granted on August 3, 2026 and consisted of options to purchase an aggregate of 139,355 shares and restricted share units or, in the case of employees in the United Kingdom nominal cost options, covering an aggregate of 66,300 shares. The options have an exercise price per share equal to $11.25, the closing price of the Company’s American Depositary Shares on the Nasdaq Global Select Market on the grant date, and will vest over a four-year period with 25% vesting on the first anniversary of the date of the grant and the remaining 75% vesting in equal monthly installments over the three-year period thereafter, subject to each employee’s continued employment. The restricted

Clinilabs Announces Medical Leadership Appointments5.8.2026 16:05:00 CEST | Press release

Bob Dagher, M.D., Named Chief Medical Officer and Waqar Ahmed Siddiqui, M.D., Named Principal Investigator Clinilabs (“Clinilabs LLC”), a global, full-service contract research organization (CRO) specializing in central nervous system (CNS) drug and device development, today announced the appointments of Bob Dagher, M.D., as Chief Medical Officer and Waqar Ahmed Siddiqui, M.D., as Principal Investigator of the Company’s Eatontown, New Jersey Clinical Research Unit (CRU). Dr. Dagher will provide strategic and medical leadership across the organization, while Dr. Siddiqui will lead the execution of research projects at the Company’s CRU. Together, they will support the design, development, and execution of clinical programs for pharmaceutical, biotechnology, and medical device sponsors advancing innovative therapies for psychiatric, neurological, substance use, and rare CNS disorders. “Clinilabs has earned the trust of sponsors by combining deep scientific expertise, medical leadership,

Interactive Brokers Adds Brazilian Futures through Brazil’s B3 Exchange5.8.2026 16:00:00 CEST | Press release

Interactive Brokers (Nasdaq: IBKR), an automated global broker, today announced that eligible clients outside of Brazil can now trade Brazilian futures in addition to equities through the B3 exchange. Interactive Brokers was the first broker to provide international investors with streamlined, low-cost access to B3. Offering Brazilian futures and equities alongside products across more than 170 markets worldwide underscores IBKR’s commitment to broadening global market access and giving clients efficient, cost-effective ways to diversify through a single, unified platform. Access to B3 provides exposure to one of Latin America’s most active and liquid markets, providing long-term growth potential across multiple sectors and another way for investors to pursue emerging market opportunities. "Global investors deserve seamless, low-cost access to the world's most compelling markets, including emerging economies shaping tomorrow's financial landscape," said Milan Galik, Chief Executive Off

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye